The only news that will be coming is an NDA filing. Based on the verbiage of the conference call it won't be until the very end of the quarter. I personally dont see a EU partner happening until late Q4/Early Q1 at the absolute earliest.
Back from lunch, shorty....what do you call this, a catalyst, or the ramblings of a long?
"With the successful completion of our Zalviso™ clinical program that includes data from all three Phase 3 studies, each of which met its primary endpoint, we are preparing to submit our New Drug Application (NDA), by the end of the third quarter," stated Richard King, president and CEO of AcelRx. "We were pleased with the financing completed last month in which we raised almost $48 million in net proceeds. This additional cash provides the resources to fund operations at least through the end of 2014 including commercial preparation activities for, and the potential launch of, Zalviso in the United States."